Exclusive: Prison and multibillion dollar buyouts later, Sam Waksal is all in on the biotech game, with some big-name backers
Sam Waksal isn’t letting a five-year prison stretch for one of the most infamous insider trading scandals in Wall Street history stop him from doing something he’s good at: steering experimental drugs through the clinic, and pointing them to the market with blockbuster valuations that earn multibillion-dollar M&A deals.
Hours after Sanofi put out word that it is paying close to $2 billion for his biotech brainchild Kadmon, Waksal spelled out his latest plans in a rare interview with Endpoints News.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.